Ozempic, Inhalers, In The Crosshairs As FTC Goes After Hundreds More ‘Junk Patents’
Teva, GSK, Boehringer, And Novartis Among Companies Targeted In Fresh Wave
The US Federal Trade Commission is not resting on its laurels after seeing some success in its initial challenge to what it deems improper or irrelevant US patents that may be strangling cheaper generic competition.
